Serum levels of inflammasome pathway factors in clinically isolated syndrome and multiple sclerosis patients: A pilot study

Basit Öğe Kaydı
dc.authorid0000-0002-9886-2017en_US
dc.contributor.authorTamam, Yusuf
dc.contributor.authorYüceer, Hande
dc.contributor.authorDüzel, Berna
dc.contributor.authorŞen, Melis
dc.contributor.authorUlusoy, Canan
dc.contributor.authorTüzün, Erdem
dc.date.accessioned2021-08-05T13:16:35Z
dc.date.available2021-08-05T13:16:35Z
dc.date.issued2020en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nöroloji Ana Bilim Dalıen_US
dc.description.abstractPathogenic roles of nuclear factor κB (Nf-κB) pathway and nlrP3 inflammasome complex factors are involved in multiple sclerosis (mS) development. activation of the Nf-κB, nlrP3, and caspase-1 cascade results in production of proinflammatory cytokines that lead to stimulation of macrophages, lymphocytes, and glial cells. although increased levels of inflammasome complex factors are observed in Ms, contribution of inflammasome pathway to conversion from clinically isolated syndrome (cis) to relapsing remitting Ms (rrMs) has been scarcely investigated. To examine predictive value of inflammasome factors in cis-Ms conversion, levels of nlrP3, caspase-1, and nFκB are measured by elisa in sera of age-gender matched cis (n = 18; 8 converting, 10 non-converting) and rrMs (n = 23) patients. cis and rrMs patients have comparable serum levels of nlrP3, caspase-1, and NfκB. similarly, no statistically significant difference can be found among converting and non-converting cis patients by means of inflammasome complex factor levels. inflammasome factors are presumably overexpressed at early stages of Ms. Therefore, they are unlikely to be used as biomarkers to predict cis-Ms conversion.en_US
dc.identifier.citationTamam, Y., Yüceer, H., Düzel, B., Şen, M., Ulusoy, C., Tüzün, E. ve diğerleri (2020). Serum levels of inflammasome pathway factors in clinically isolated syndrome and multiple sclerosis patients: A pilot study. Central European Journal of Immunology, 45(2), 237-240.en_US
dc.identifier.doi10.5114/ceji.2020.96877
dc.identifier.endpage240en_US
dc.identifier.issn1426-3912
dc.identifier.issue2en_US
dc.identifier.pmid33456338
dc.identifier.scopus2-s2.0-85093673812
dc.identifier.scopusqualityQ3
dc.identifier.startpage237en_US
dc.identifier.urihttps://www.termedia.pl/Serum-levels-of-inflammasome-pathway-factors-in-clinically-isolated-syndrome-and-multiple-sclerosis-patients-a-pilot-study,10,41163,0,1.html
dc.identifier.urihttps://hdl.handle.net/11468/7260
dc.identifier.volume45en_US
dc.identifier.wosWOS:000559731700018
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTamam, Yusuf
dc.institutionauthorDüzel, Berna
dc.language.isoenen_US
dc.publisherTermedia Publishing House Ltd.en_US
dc.relation.ispartofCentral European Journal of Immunology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCaspase-1en_US
dc.subjectClinically isolated syndromeen_US
dc.subjectMultiple sclerosisen_US
dc.subjectNeuroinflammationen_US
dc.subjectNfκBen_US
dc.subjectNlrP3en_US
dc.titleSerum levels of inflammasome pathway factors in clinically isolated syndrome and multiple sclerosis patients: A pilot studyen_US
dc.titleSerum levels of inflammasome pathway factors in clinically isolated syndrome and multiple sclerosis patients: A pilot study
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Serum levels of inflammasome pathway.pdf
Boyut:
117.53 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu